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Abstract
Background: Primary diffuse leptomeningeal gliomatosis (PDLG) is a very rare neuro-oncological disease, with only
90 cases of PDLG described in medical literature so far.
Case presentation: We present a case report of a 56-years-old female patient, who was originally hospitalized due
to cervical spine pain lasting several months. Despite complex diagnostics and treatment, the neurological state of
the patient progressively deteriorated. Patient died 10 months after the first reported symptom. Postmortem
pathological findings resulted in the diagnosis of PDLG.
Conclusions: Affection of the cervical spine in early stages of PDLG is rare and has been described in only six
patients so far. PDLG is a fatal neuro-oncological disease and it must be kept in mind in the differential diagnosis of
persistent back pain syndromes.
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Background
Meningeal (leptomeningeal) gliomatosis is defined as in-
filtration of subarachnoidal spaces by glial tumor cells.
There are two types - primary and secondary meningeal
gliomatosis. Secondary leptomeningeal gliomatosis occurs
in 8–27 % of patients with primary malignant glioma in
the brain or spinal cord. On the other hand, primary dif-
fuse leptomeningeal gliomatosis (PDLG) shows no signs
of tumor cells in brain or spinal cord tissue. It is a rare
neuro-oncological disease, with only 90 cases of PDLG de-
scribed in medical literature so far [1, 2].
We present a case report of a female patient with
PDLG, who was originally hospitalized due to cervical
spine pain lasting several months.
Case presentation
Our 56-years-old patient (with a history of seropositive
rheumatoid arthritis treated by methotrexate since 2005)
had been complaining about fluctuating cervical spine
pain radiating to occipital region since June 2013. In the
beginning of November 2013 the pain worsened and led
to 2-week hospitalization with intensive analgesic treat-
ment. On 27/Oct/2013, during ordinary daily activities,
she suddenly stopped communicating and looked fixedly
in front of her. In hospital, neurological examination re-
vealed perceptive and expressive aphasia as well as palpi-
tation pain in cervical paravertebral muscles with no
signs of meningeal irritation. Due to suspected vascular
etiology with normal brain CT findings and fulfilled time
window criteria, we indicated intravenous thrombolysis
and the patient rapidly improved ad integrum. Another
possible diagnosis we considered was partial complex
epileptic seizure. Psychological examination revealed
mildly impaired memory and executive faculties. The
other tests performed (internal and ophtalmological
examination, EEG, carotid and vertebral artery ultra-
sound, and CT angiography of intracranial arteries)
showed normal findings. Patient was discharged from
the hospital with appointments set for further tests of
thrombophilic states and MRI of brain and spinal cord.
On 18/Dec/2013 the patient was again admitted to
Neurological clinic due to sudden onset of aphasia with
desorientation followed by secondary generalized tonic-
clonic epileptic seizure, which improved after symptom-
atic treatment with diazepam. On neurological examin-
ation the patient reported pain in cervical region with
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no sign of meningeal irritation, had lower limb hyperre-
flexia, and mild paraparetic-ataxic gait. Brain and spinal
cord MRI showed diffuse hyperintensity in hippocampus
bilaterally, in brainstem and cerebellum, and in spinal
cord grey matter up to segment Th7-8 (Fig. 1). Proton
single-voxel MRI spectroscopy revealed no definite
pathological metabolic changes in voxel placed in hyper-
intensive brainstem. There were no signs of cerebro-
spinal fluid flow obstructions. Cerebrospinal fluid
showed massive increase in proteins (12 g/l), increased
albumin (4.0 g/l), mild increase in cell count (monocytes
22/3, lymphocytes 5/3) and CD4/8 index (2.94) based on
flow cytometry analysis. No oligoclonal bands and eryth-
rocytes were detected. Normal findings were in the fol-
lowing tests: complete blood count, coagulation, basic
metabolic panel, oncomarkers (CEA, Ca 72–4, Ca 15–3,
Ca 125, Ca 19–9, CYFRA 21–1, SCC antigen), hormons
(PRL, FT4, TSH), pathogen tests (lues, borrelia, chla-
mydia, mycoplasma, EBV, CMV, HSV1, HSV2, VZV,
HIV, TBC, toxoplasma, rubeola), antineural IgG anti-
bodies (anti-Ri, Yo, Hu, PNMA2, CV2, amphiphysin),
and wide spectrum of autoantibodies (anti- nRNP, anti-
Sm, anti- Ro-52, anti- SS-A, anti- SS-B, anti- Scl-70,
anti- PM-Scl, anti- Jo-1, anti- CENP B, anti- dsDNA,
anti- histone, anti- nucleosome, anti- ribosomal P pro-
tein, anti- mitochondrial M2 subtype, anti-tissue trans-
glutaminase, anti-gliadin, anti-EMA, anti- cardiolipin).
FDG - PET examination showed increased metabolism
regions in meninges in several places: in cervical and thora-
cical spinal cord, in infratentorial regions, and partially on
brain convexity (Figs. 2 and 3). The most probable diagno-
sis was autoimunne meningoencephalitis with secondary
epilepsy. During the long-term hospitalization patient was
treated with methylprednisolon (overall dose 5 g), plasma-
pheresis (3 times), intravenous immunoglobins (0.4 g/kg/
day for 5 days), and empirically with acyclovir and
ceftriaxone.
Despite extensive treatment the patient progressivelly
deteriorated, she developed central lesion of right facial
nerve, left upper limb dysmetria, and mild spastic lower-
limb paraparesis. She suffered repeated epileptic seizures
Fig. 1 Diffuse T2/FLAIR hyperintensity in cerebellum, brainstem and
cervical spinal cord (arrows)
Fig. 2 Half-body FDG-PET showing intense uptake along the brain-
stem, cerebellum, cervical and thoracical spinal cord (arrow)
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despite combination of antiepileptic treatment with carba-
mazepine (2 × 300 mg), levetiracetam (2 × 1000 mg), and
lamotrigine (2 × 25 mg). At the beginning of February
2014 the patient began to be somnolent and later semi-
comatose. Brain MRI showed hydrocephalus with en-
largement of all four ventricles, and there was bilateral
optic papilla oedema with haemorrhage. External lum-
bar drainage led to mild improvement - the patient was
somnolent with meningeal irritation, she was blind with
organic psychosyndrome. Cerebrospinal fluid again
showed massive hyperproteinorrhachia (12.9 g/l), pleo-
cytosis (monocytes 52/3, lymphocytes 2/3). Interictal
EEG showed mildly abnormal background activity with
mixed (slow and epileptiform) regional abnormality in
bilateral temporal regions. At the end of February MRI
showed mild decrease in intensity od signal in hippo-
campus, brainstem, cerebellum, and in spinal cord, and
remaining hydrocephalus. Meninges were enhanced in
frontoparietal regions with MRI contrast aplication.
Despite the treatment and complex care, neurological
state progressively deteriorated. During April patient
developed severe bronchopneumonia with sepsis, left
subclavian vein thrombosis followed by multiorgan
failure. Patient died on 26/Apr/2014, approximately
10 months after the first report of cervical spine pain.
The autopsy verified pathology in leptomeninges of me-
dulla oblongata, pons and basal parts of hemispheres. This
was extensive tumour infiltration mainly consisting of
medium-sized cells with eosinophilic cytoplasm and oval
nuclei with granular chromatin, as well as a number of big,
multinuclear cells, and cells with large, dense, bizarre nuclei
and numerous mitoses including atypical mitoses. Foci of
vessel proliferation were also present. Imunohistochemical
staining revealed glial fibrillary acid protein (GFAP), S-100
protein, epithelial membrane antigen (EMA), but no signs
of CD68 antigen. Biopsy resulted in the diagnosis of glio-
blastoma multiforme. Despite sampling of whole brain and
spinal cord tissue, no similar tumorous lesion was found.
These findings match criteria for PDLG (Figs. 4, 5, 6 and 7).
Conclusions
Since the first description of PDLG in 1923, less than 90
cases have been described so far [1–3]. It is supposed
that heterotopic location of glial cells in leptomeninges
most probably occurs during embryogenesis. In general
population it is present in about 1 % of autopsies and up
to 25 % of autopsies of patients with CNS malformations
[4]. The age ranges between 1 and 84, with average sur-
vival of 4 months [5, 6].
CSF fluid obstruction can be caused by increased amount
of proteins in CSF, or tumour-caused subarachnoidal bleed-
ing, infiltration of basal subarachnoidal cisterns, or venous
sinuses compression [7]. In our 56-year-old patient hydro-
cephalus was developed at a later stage of the disease
(7 months after first cervical pain). We consider infiltration
of subarachnoidal spaces in basal brain regions together
with CSF resorbtion impairment due to hyperproteinorrha-
chia (up to 12.9 g/l) to be the main cause of hydrocephalus.
Other typical early signs of the disease are cranial n-
europathies (in 56 % of patients), meningeal irritation
(44 %) and epileptic seizures (44 %) [8, 9]. In our pa-
tient meningeal irritation occured at a later stage
(7–8 months after the first symptoms). The first
symptom was treatment-resistant neck pain. It was
followed by repeated partial complex epileptic seizures
(the first was considered as ischemic stroke with aphasia)
5 months later, and by development of focal spinal neuro-
logical deficit (paraparetic-ataxic gait with hyperreflexion
in lower limbs). Affection of cervical spine in early stages
of PDLG is rare and has been described in only six pa-
tients [6, 7, 9–12]. The most common early-stages PDLG
location is supratentorial [8, 9].
Fig. 3 FDG-PET showing increased uptake in infratentorial regions,
and partially on brain convexity
Fig. 4 Diffuse infiltration of leptomeninges by tumorous cells,
without formation of macroscopically identifiable mass, without
infiltration of brain parenchyme. Hematoxylin-eosin stain (20x)
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We explain our patient’s diffuse T2/FLAIR hyperintensity
in temporal lobes, brainstem, cerebellum, and in proximal
spinal cord to be intraparenchymal oedema developed due
to microcirculation impairment caused by tumor infiltra-
tion of subarachnoidal spaces. Similar findings were de-
scribed by other authors [9, 13]. We suppose this to be the
cause of our patient’s early neurological symptoms.
Brain MRI in the begining of the disease usually shows
normal findings. Later on hydrocephalus is developed, and
diffuse thickening and contrast enhancement of the lepto-
meninges occurs [2, 14]. CSF examination typically shows
increased CSF pressure, hyperproteinorrhachia (up to
12.9 g/l in our patient) and lymphocytic pleocytosis with
normal or lowered glucose amount can be present [15, 16].
Unlike leptomeningeal carcinomatosis and secondary
meningeal gliomatosis, cytologic CSF examination is usually
not sensitive enough in PDLG [17, 18]. It is usually a biopsy
from the site of leptomeningeal thickening that confirms the
diagnosis [14].
PDLG is included in the large differential diagnosis of
subacute and chronic meningitis/meningoencephalitis and
meningeal tumours [19, 20]. Morphological subtypes of
PDLG are glioblastoma multiforme, high-grade astrocy-
toma, oligodendroglioma, gliosarcoma, and occassionally
pilocytic astrocytoma. Other tumours primarily affecting
leptomeninges are ependymoblastoma, primitive neuroec-
todermal tumour, melanocytoma, and lymphomas [14].
There is no standard therapy of the disease at present [9]. It
is important to treat the symptoms (e.g. analgesics, antiepi-
leptic therapy, shunt implantation). In early diagnosis of
low-grade tumours, case reports suggest the efficacy of
chemotherapy (systemic, intrathecal, and intraventricular),
and radiotherapy (brain, spinal cord) in prolonged survival
of patients [5, 6, 21].
PDLG is a very rare, fatal neuro-oncological disease
and it must be kept in mind in the differential diagnosis
of persistent back pain syndromes.
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Fig. 5 Tumorous mass composed of pleomorphous cells with
abundant eosinophilic cystoplasm and variable sized nuclei with
pale chromatin and small nucleoli. Tumorous cells with large,
irregular, hyperchromatic nuclei and multinucleated cells are
intermingled. Hematoxylin-eosin stain (100x)
Fig. 6 Diffuse cytoplasmatic immunohistochemical positivity of glial
fibrillary acidic proteine (GFAP) proves the glial/astrocytic
differentiation of tumorous burden (DAKO antibody 40x)
Fig. 7 Localised vascular proliferation including s.c. glomeruloid
formations characteristic for glioblastomas. Hematoxylin-eosin
stain (100x)
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